Biomea Fusion (BMEA)
NASDAQ:BMEA
Want to see BMEA full AI Analyst Report?
BMEA Stock Chart & Stats
$2.21
$0.07(1.75%)
At close: 4:00 PM EST
$2.21
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $3.08
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$115.68M
Enterprise Value$42.76M
Total Cash (Recent Filing)$55.81M
Total Debt (Recent Filing)$1.59M
Price to Earnings (P/E)4.9
Beta1.78
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding72,299,440
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-45.15
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$7.00Price Target Upside216.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Confirmatory Clinical TrialsAnalyst's recommendation is supported by ongoing confirmatory Phase 2 trials of icovamenib in defined type 2 diabetes subgroups that could enable later-stage development.
Durable Clinical SignalsLong-term midstage results showing durable increases in endogenous insulin markers and sustained improvements in blood glucose support the drug's mechanism and potential for lasting benefits after treatment.
Pipeline Diversification And DosingAdvancement of an oral GLP-1 candidate combined with a food-effect study showing favorable drug exposure and safety when dosed with a meal expands commercial diversification and helps optimize dosing strategy.
Bears Say
Financing Overhang RiskA financing overhang presents a material risk that could delay critical development programs or force dilutive capital raises if not resolved.
Funding ConcernsAnalyst reiterates an Underweight rating due to funding concerns for the lead drug and broader pipeline, indicating potential constraints on program advancement without additional capital.
Trial Outcome Concentration RiskAnalyst notes that the company's outlook depends on successful outcomes from multiple clinical trials, leaving the stock vulnerable to negative trial results or delays.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $3.08 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $115.68M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Aug 03, 2026 which is in 87 days.
How were Biomea Fusion’s earnings last quarter?
Currently, no data Available
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 72,299,440 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (216.74% Upside)
$7.00 (216.74% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-243.73%
Trailing 12-Months
Asset Growth
-26.73%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$7.00
▲(216.74% Upside)
Technical Analysis
Ownership Overview
8.66% Insiders
11.22% Mutual Funds
3.73% Other Institutional Investors
72.68% Public Companies and
Individual Investors